Mobic (Meloxicam)

Meloxicam works by reversibly inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, with a preference for COX‑2. This inhibition reduces the conversion of arachidonic acid to prostaglandins, which are mediators of inflammation, pain, and fever, thereby providing symptomatic relief.

The specific dose and frequency of Mobic are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare providers adjust the regimen to achieve optimal pain control while minimizing potential adverse effects.

Safety data for meloxicam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally avoided during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant.

To request Mobic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mobic (meloxicam) offers a longer half‑life and preferential COX‑2 inhibition compared with many traditional NSAIDs such as ibuprofen or diclofenac. This can allow once‑daily dosing and may reduce gastrointestinal irritation, though the overall safety profile remains similar, requiring caution in patients with renal or cardiovascular risk.

Mobic should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vial from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Mobic is supplied as an injectable solution for intramuscular (IM) administration. A qualified healthcare professional injects the prescribed volume into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and standard injection guidelines.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as myocardial infarction or stroke, acute renal impairment, severe skin reactions (e.g., Stevens‑Johnson syndrome), and anaphylactic reactions. Patients should be monitored for signs of these events, especially if they have pre‑existing risk factors.

Mobic is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, and in patients where pregnancy or breastfeeding poses a risk. Clinicians should also avoid use in patients with significant renal or hepatic impairment unless benefits clearly outweigh risks.